Sector News

Phil Schiller, Apple's marketing chief, is now a director of Illumina

August 1, 2016
Life sciences

Phil Schiller, Apple’s marketing chief, is now a director of Illumina, one of the most important companies in gene sequencing.

Illumina has an enormous presence in the life science industry. It makes the machines and develops technology used for genetic testing, and counts companies like 23andMe as customers. It has a market capitalization of $25 billion.

If you’ve had your genes sequenced, in one of those consumer genetic tests like 23andMe for instance, it was most likely on an Illumina machine. 90% of human genetic sequencing takes place on Illumina machines.

Earlier this year, Apple’s ResearchKit platform — which is being explored for uses in drug development — began to support studies that use 23andme genetic information.

“Illumina is like the ruler of this whole universe and no one knows that,” 23andMe’s CEO Anne Wojcicki told Fast Company.

“Phil’s track record and global experience in bringing world-class products to market will help guide us as we continue to develop innovative new solutions for our customers,” Francis deSouza, Illumina president said in a statement.

Apple has health ambitions
Schiller has been with Apple since 1997 and works to define the company’s product lines and strategy. He’s a key advisor to CEO Tim Cook and frequently presents the newest iPhone at Apple keynote presentations.

Apple as a company has a deep interest in health and its Apple Watch is a way to break into the medical world. Apple executives talk about simplifying health care as a major focus and mission — it’s even hired nurses to staff labs to do round-the-clock biometric testing.

“We believe that health is something that is a huge problem in the world, and we think it is ripe for simplicity and a new view, and we’d like to contribute to that,” Apple CEO Tim Cook said at a conference earlier this year.

Apple’s health division reports to Apple COO Jeff Williams, not Schiller. And Schiller joining his first board of directors in the health space could signal an expansion of Apple’s medical ambitions given his product focus.

Previously, Apple was looking to hire a medical privacy specialist who could consult on mergers and acquisitions, and hired the CEO of Sage Bionetworks, which handles much of the consent and back-end functions for Apple’s health software.

Source: Illumina

comments closed

Related News

September 17, 2022

Novo Nordisk partners with Microsoft for AI-driven drug discovery

Life sciences

Novo Nordisk has signed a new strategic partnership with Microsoft to expedite the discovery and development of drugs leveraging big data and artificial intelligence (AI). Under the deal, Microsoft’s computational services, Cloud and artificial intelligence (AI) will be merged with the drug discovery, development and data science expertise of Novo Nordisk.

September 17, 2022

Bayer’s hunt for a new CEO is on, suggesting Werner Baumann could be headed for an early exit: report

Life sciences

Following years of push-and-pull over the German conglomerate’s top post, Bayer has quietly started a hunt for Baumann’s successor, Bloomberg News reported Tuesday, citing people close to the matter. The new CEO search may portend an early departure for Baumann, whose contract with Bayer isn’t set to expire until April 2024.

September 17, 2022

Bluebird CFO resigns ahead of gene therapy launch

Life sciences

Bluebird bio on Monday said its chief strategy and financial officer, Jason Cole, will leave the company this fall, marking the second time in less than a year the cash-strapped gene therapy developer will replace its top financial executive.